PMC9702560_01
Survival analysis (PFS and OS) according to age and gender. Survival analysis (PFS and OS) of G12 patients according to age (panels A and C) and gender (panel B and D). (A) mPFS of patients < 65 years (n = 62) vs. patients > 65 years (n = 119): 6.0 months (95% CI 4.0-11.0 months) vs. 4.0 months (95% CI 4.0-6.0 months), p = 0.518. (B) mPFS of female (n = 71) vs. male (n = 110): 6.0 months (95% CI 4.0-11.0 months) vs. 4.0 months (95% CI 3.0-6.0 months), p = 0.013. (C) mOS of patients < 65years (n = 56) vs. patients > 65 years (n = 109): 20.5 months (95% CI 10.0-NR months) vs. 13.0 months (95% CI 9.0-17.0 months), p = 0.007. (D) mOS of female (n = 63) vs. male (n = 102): 23.0 months (95% CI 18.0-NR months) vs. 14.5 months (95% CI 9.0-17.0 months), p = 0.004.
fonc-12-968064-g002.jpg
PMC9702560_01_fonc-12-968064-g002.jpg
f2
ICI with or without CT showed a benefit compared to chemotherapy alone (HR: 0.63, 95% CI 0.45-0.87, p = 0.005) in univariate and multivariate analysis ( Table 2 ) ( Figures 2A, B ). In particular, we registered a mOS of 17.0 months (13.0-29.0 months) for the C isoform (n = 79), a mOS of 13.5 months (6.0-26.0 months) for D (n = 28), a mOS of 21.0 months (7.0-NR months) for the A substitution (n = 13), and a mOS of 12.0 months (8.0-18.0 months) for the V substitution (n = 35), which proved to be the mutation with the worst prognosis. Table 3 ) ( Figures 2C, D ). The benefit of young age and female gender was confirmed also in the multivariate analysis.
PFS according to single amino acid substitutions in patients treated with ICI +- CT (n = 94). (A) mPFS C (n = 43) vs. V (n = 19): 4.0 months (95% CI 4.0-18.0 months) vs. 4.0 months (95% CI 3.0-12.0 months), p = 0.114. (B) mPFS D (n = 16) vs. V (n = 16): 8.0 months (95% CI 6.0-NR months) vs. 4.0 months (95% CI 3.0-12.0 months), p = 0.165. (C) mPFS A (n = 10) vs. V (n = 16): 9.0 months (95% CI 4.0-NR months) vs. 4.0 months (95% CI 3.0-12.0 months), p = 0.140.
fonc-12-968064-g003.jpg
PMC9702560_01_fonc-12-968064-g003.jpg
f3
ICI ( Figures 3A-C ). Interestingly, despite mPFS being similar in the two groups, we highlighted a favorable trend in PFS for C compared with the V isoform (p = 0.114) ( Figure 3A ). As shown in the figure, a similar trend was also described for D (p = 0.165) and A (p = 0.140) mutations when compared to V ( Figures 3B, C ).